• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by XORTX Therapeutics Inc.

    10/31/24 10:28:13 AM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XRTX alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001729214
    APAC Resources Inc.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    XORTX Therapeutics Inc.
    Jurisdiction of Incorporation/Organization
    BRITISH COLUMBIA, CANADA
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    XORTX Therapeutics Inc.
    Street Address 1 Street Address 2
    3710 - 33rd Street NW
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    Calgary ALBERTA, CANADA T2L 2M1 403-455-7727

    3. Related Persons

    Last Name First Name Middle Name
    Davidoff Allen
    Street Address 1 Street Address 2
    3710 - 33rd Street NW
    City State/Province/Country ZIP/PostalCode
    Calgary ALBERTA, CANADA T2L 2M1
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Evans Stacy
    Street Address 1 Street Address 2
    3710 - 33rd Street NW
    City State/Province/Country ZIP/PostalCode
    Calgary ALBERTA, CANADA T2L 2M1
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Fairbairn James
    Street Address 1 Street Address 2
    3710 - 33rd Street NW
    City State/Province/Country ZIP/PostalCode
    Calgary ALBERTA, CANADA T2L 2M1
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Haworth Stephen
    Street Address 1 Street Address 2
    3710 - 33rd Street NW
    City State/Province/Country ZIP/PostalCode
    Calgary ALBERTA, CANADA T2L 2M1
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Farley William
    Street Address 1 Street Address 2
    3710 - 33rd Street NW
    City State/Province/Country ZIP/PostalCode
    Calgary ALBERTA, CANADA T2L 2M1
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Giovinazzo Anthony J.
    Street Address 1 Street Address 2
    3710 - 33rd Street NW
    City State/Province/Country ZIP/PostalCode
    Calgary ALBERTA, CANADA T2L 2M1
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Jenkins Abigail
    Street Address 1 Street Address 2
    3710 - 33rd Street NW
    City State/Province/Country ZIP/PostalCode
    Calgary ALBERTA, CANADA T2L 2M1
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Pratt Raymond
    Street Address 1 Street Address 2
    3710 - 33rd Street NW
    City State/Province/Country ZIP/PostalCode
    Calgary ALBERTA, CANADA T2L 2M1
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Treanor Patrick
    Street Address 1 Street Address 2
    3710 - 33rd Street NW
    City State/Province/Country ZIP/PostalCode
    Calgary ALBERTA, CANADA T2L 2M1
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Van Damme Paul
    Street Address 1 Street Address 2
    3710 - 33rd Street NW
    City State/Province/Country ZIP/PostalCode
    Calgary ALBERTA, CANADA T2L 2M1
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
    X
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-10-18    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
    X Yes    No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security X Other (describe)
    One warrant entitles the holder thereof to purchase one common share of the Company at an exercise price of US$2.18 per share for a period of five years following the issuance of the warrants.

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    A.G.P./Alliance Global Partners 8361
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    88 Post Road West Floor 2
    City State/Province/Country ZIP/Postal Code
    Westport CONNECTICUT 06880
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    NEW YORK

    13. Offering and Sales Amounts

    Total Offering Amount $1,767,566 USD
    or    Indefinite
    Total Amount Sold $0 USD
    Total Remaining to be Sold $1,767,566 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    The $1,767,566 may be received upon the exercise of share purchase warrants sold inside and outside the U.S.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $105,000 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors.

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    XORTX Therapeutics Inc. /s/ Allen Davidoff Allen Davidoff Chief Executive Officer 2024-10-30

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $XRTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XRTX

    DatePrice TargetRatingAnalyst
    12/9/2021$11.00Buy
    Alliance Global Partners
    More analyst ratings

    $XRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on XORTX Therapeutics with a new price target

    Alliance Global Partners initiated coverage of XORTX Therapeutics with a rating of Buy and set a new price target of $11.00

    12/9/21 9:10:32 AM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XRTX
    SEC Filings

    View All

    SEC Form 6-K filed by XORTX Therapeutics Inc.

    6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

    1/2/26 2:37:30 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by XORTX Therapeutics Inc.

    6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

    11/17/25 4:17:20 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by XORTX Therapeutics Inc.

    6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

    10/31/25 4:15:52 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

    CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that further to its press release of October 17, 2025 and an update on December 31, 2025, the Company has entered into an extension agreement with Vectus Biosystems Limited ("Vectus") to allow further time to complete the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus (the "Acquisition"). The term sheet entered into October 17th (the "Term Sheet") to acquire the novel new chemical

    2/4/26 6:00:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

    CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, highlights recent peer-reviewed, independent, published research reports that expand current knowledge that genetic factors are linked to the over-expression of xanthine oxidase ("XO"), high chronic uric acid concentrations in the blood and gout. These ground breaking findings further support the Company's approach to treating gout, kidney and other diseases by inhibiting XO. Historically, high uric acid concentra

    12/31/25 6:15:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XORTX Announces Closing of US$1.1 Million Registered Direct Offering

    CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its registered direct offering announced on October 21, 2025, for the purchase and sale of 1,750,000 common shares (the "Common Shares") (or pre-funded warrants (the "Pre-Funded Warrants") in lieu thereof) in a registered direct offering (the "Offering") at a purchase price of US$0.63 per common share. In connection with the Offering, the Company entered into a definitive securities pu

    10/29/25 7:00:00 AM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XRTX
    Leadership Updates

    Live Leadership Updates

    View All

    XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

    CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that further to its press release of October 17, 2025 and an update on December 31, 2025, the Company has entered into an extension agreement with Vectus Biosystems Limited ("Vectus") to allow further time to complete the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus (the "Acquisition"). The term sheet entered into October 17th (the "Term Sheet") to acquire the novel new chemical

    2/4/26 6:00:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XORTX Announces Results of Annual and Special Meeting of Shareholders

    CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the "Meeting") held Thursday, September 12, 2024. A total of 889,288 common shares of the Company were represented at the Meeting, representing approximately 31% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including electi

    9/13/24 7:00:00 AM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XORTX Welcomes New Member to the Board of Directors

    CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv

    4/8/24 7:30:00 AM ET
    $GMDA
    $XRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $XRTX
    Financials

    Live finance-specific insights

    View All

    XORTX Announces Date for Rescheduled Special Meeting of Shareholders

    CALGARY, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its earlier press release, the special meeting of shareholders has been rescheduled to 10:00 a.m. (Calgary time) on Friday, October 27, 2023 (the "Meeting"). At the Meeting shareholders will consider a consolidation of the Company's issued and outstanding shares in order for the Company to regain compliance with the continued listing requirements for the NASDAQ Capital Market. About XORTX Therap

    10/25/23 5:00:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XORTX Therapeutics Announces Annual and Special Meeting of Shareholders

    CALGARY, Alberta, Nov. 23, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (TSXV:XRTX, NASDAQ:XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces that it will hold its annual and special meeting of shareholders at 11:00 a.m. (Calgary time) on Monday, December 20, 2021 (the "Meeting"). Materials for the Meeting have been mailed to shareholders and are available on the Company's SEDAR profile and the Company's website. The meeting has been called for shareholders to consider annual matters including the election of directors, re-appointment of Smythe LLP Chartered Accountants as au

    11/23/21 7:00:00 AM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by XORTX Therapeutics Inc. (Amendment)

    SC 13G/A - XORTX Therapeutics Inc. (0001729214) (Subject)

    2/14/24 3:03:47 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by XORTX Therapeutics Inc.

    SC 13G - XORTX Therapeutics Inc. (0001729214) (Subject)

    2/14/23 1:48:46 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care